Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491664 | 0.79 | RNASEH1 (0.58) | RNASEH1SMN1; SMN2 | |
| SCHEMBL3492404 | 0.78 | LMNA (0.44) | RNASEH1SMN1; SMN2 | |
| SCHEMBL3492427 | 0.78 | KMT2A (0.60) | RNASEH1SMN1; SMN2 | |
| SCHEMBL3492896 | 0.78 | RNASEH1 (0.57) | RNASEH1SMN1; SMN2 | |
| SCHEMBL3494017 | 0.77 | LMNA (0.46) | RNASEH1 | |
| SCHEMBL4512178 | 0.77 | KDM4E (0.58) | SMN1; SMN2 | |
| SCHEMBL27726590 | 0.72 | NPSR1 (0.50) | SMN1; SMN2 | |
| SCHEMBL27726659 | 0.71 | KDM4E (0.41) | — | |
| SCHEMBL3494842 | 0.71 | MAPT (0.58) | RNASEH1SMN1; SMN2 | |
| Acetic Acid SCHEMBL2245496 | 0.70 | HTR6 (0.56) | RNASEH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10822346-B2 | Meglumine salts of thienopyrimidines | CARDURION PHARMACEUTICALS, LLC (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2019204298-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822346-B2 | Meglumine salts of thienopyrimidines | DPYD, TPMT, TYMP | RNASEH1 1071/4885SMN1; SMN2 586/4885 |
| US-20190315765-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | RNASEH1 1071/4885SMN1; SMN2 586/4885 |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | RNASEH1 1071/4885SMN1; SMN2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.